Biotech

PDL Biopharma today announces that it will sell $150.0 million aggregate principal amount of its 2.75% Convertible Senior Notes due 2021 in an underwritten public offering.

PDL BioPharma (NASDAQ:PDLI) today announces that it will sell $150.0 million aggregate principal amount of its 2.75% Convertible Senior Notes due 2021 in an underwritten public offering.
According to the press release:

The conversion rate of the Notes will initially be 262.2951 shares of common stock per $1,000 principal amount of the Notes, equivalent to an initial conversion price of approximately $3.81 per share of common stock, subject to adjustment.  The net proceeds from the offering, after deducting the underwriters discount and other estimated offering expenses are expected to be approximately $145.8 million.

Read the full press release here.

MARKETS

Markets
TSX19062.91+345.79
TSXV647.33+15.54
DOW31500.68+823.32
S&P 5003911.74+116.01
NASD11607.62+375.43
ASX6528.40+19.90

COMMODITIES

Commodities
Gold1837.28+6.26
Silver21.46+0.33
Copper3.79+0.05
Palladium1937.00+60.00
Platinum918.50+7.50
Oil107.98+0.36
Heating Oil4.25+0.01
Natural Gas6.11-0.12

DOWNLOAD FREE REPORTS

×